 Adverse Drug Reaction Reporting Systems
"Adverse Drug Reaction Reporting Systems" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions.
| Descriptor ID |
D016907
|
| MeSH Number(s) |
E05.337.800.120 N02.421.668.320.120
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Adverse Drug Reaction Reporting Systems".
Below are MeSH descriptors whose meaning is more specific than "Adverse Drug Reaction Reporting Systems".
This graph shows the total number of publications written about "Adverse Drug Reaction Reporting Systems" by people in this website by year, and whether "Adverse Drug Reaction Reporting Systems" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 | | 2003 | 0 | 1 | 1 | | 2004 | 1 | 0 | 1 | | 2006 | 1 | 0 | 1 | | 2007 | 2 | 1 | 3 | | 2008 | 0 | 3 | 3 | | 2010 | 1 | 1 | 2 | | 2011 | 2 | 3 | 5 | | 2012 | 1 | 1 | 2 | | 2013 | 2 | 2 | 4 | | 2014 | 2 | 2 | 4 | | 2015 | 3 | 0 | 3 | | 2016 | 3 | 1 | 4 | | 2017 | 3 | 4 | 7 | | 2018 | 1 | 1 | 2 | | 2019 | 1 | 1 | 2 | | 2021 | 0 | 5 | 5 | | 2022 | 1 | 3 | 4 | | 2023 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Adverse Drug Reaction Reporting Systems" by people in Profiles.
-
Kurlandsky KE, Stein AB, Hambidge SJ, Weintraub ES, Williams JTB. Reporting of Race and Ethnicity in the Vaccine Safety Datalink, 2011-2022. Am J Prev Med. 2024 01; 66(1):182-184.
-
Killam-Worrall L, Brand R, Castro JR, Patel DS, Huynh K, Lindley B, Torres BP. Baclofen and Tizanidine Adverse Effects Observed Among Community-Dwelling Adults Above the Age of 50 Years: A Systematic Review. Ann Pharmacother. 2024 May; 58(5):523-532.
-
Hause AM, Shay DK, Klein NP, Abara WE, Baggs J, Cortese MM, Fireman B, Gee J, Glanz JM, Goddard K, Hanson KE, Hugueley B, Kenigsberg T, Kharbanda EO, Lewin B, Lewis N, Marquez P, Myers T, Naleway A, Nelson JC, Su JR, Thompson D, Olubajo B, Oster ME, Weintraub ES, Williams JTB, Yousaf AR, Zerbo O, Zhang B, Shimabukuro TT. Safety of COVID-19 Vaccination in United States Children Ages 5 to 11 Years. Pediatrics. 2022 08 01; 150(2).
-
Yerneni S, Shah SN, Blackley SV, Ortega CA, Blumenthal KG, Goss F, Seger DL, Wickner PG, Mancini CM, Bates DW, Zhou L. Heterogeneity of Drug Allergies and Reaction Lists in Two U.S. Health Care Systems' Electronic Health Records. Appl Clin Inform. 2022 05; 13(3):741-751.
-
Zahradka I, Petr V, Magicova M, Viklicky O. Background risk should be taken into account when reporting vaccine effectiveness. Am J Transplant. 2022 07; 22(7):1927-1928.
-
Oliver SE, Wallace M, See I, Mbaeyi S, Godfrey M, Hadler SC, Jatlaoui TC, Twentyman E, Hughes MM, Rao AK, Fiore A, Su JR, Broder KR, Shimabukuro T, Lale A, Shay DK, Markowitz LE, Wharton M, Bell BP, Brooks O, McNally V, Lee GM, Talbot HK, Daley MF. Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices - United States, December 2021. MMWR Morb Mortal Wkly Rep. 2022 Jan 21; 71(3):90-95.
-
Mbaeyi S, Oliver SE, Collins JP, Godfrey M, Goswami ND, Hadler SC, Jones J, Moline H, Moulia D, Reddy S, Schmit K, Wallace M, Chamberland M, Campos-Outcalt D, Morgan RL, Bell BP, Brooks O, Kotton C, Talbot HK, Lee G, Daley MF, Dooling K. The Advisory Committee on Immunization Practices' Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines - United States, 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1545-1552.
-
Rosenblum HG, Hadler SC, Moulia D, Shimabukuro TT, Su JR, Tepper NK, Ess KC, Woo EJ, Mba-Jonas A, Alimchandani M, Nair N, Klein NP, Hanson KE, Markowitz LE, Wharton M, McNally VV, Romero JR, Talbot HK, Lee GM, Daley MF, Mbaeyi SA, Oliver SE. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 13; 70(32):1094-1099.
-
Gargano JW, Wallace M, Hadler SC, Langley G, Su JR, Oster ME, Broder KR, Gee J, Weintraub E, Shimabukuro T, Scobie HM, Moulia D, Markowitz LE, Wharton M, McNally VV, Romero JR, Talbot HK, Lee GM, Daley MF, Oliver SE. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021 Jul 09; 70(27):977-982.
-
Costello A, Pandita A, Devitt J. Case Report: Thrombotic Thrombocytopenia after COVID-19 Janssen Vaccination. Am Fam Physician. 2021 06 01; 103(11):646-647.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|